Pulmonx Research and Development Expenses 2019-2024 | LUNG
Pulmonx research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
| Pulmonx Annual Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2023 | $18 |
| 2022 | $15 |
| 2021 | $13 |
| 2020 | $7 |
| 2019 | $6 |
| 2018 | $7 |
| Pulmonx Quarterly Research and Development Expenses (Millions of US $) |
|
|---|---|
| 2024-09-30 | $4 |
| 2024-06-30 | $6 |
| 2024-03-31 | $4 |
| 2023-12-31 | $4 |
| 2023-09-30 | $4 |
| 2023-06-30 | $6 |
| 2023-03-31 | $4 |
| 2022-12-31 | $4 |
| 2022-09-30 | $4 |
| 2022-06-30 | $4 |
| 2022-03-31 | $4 |
| 2021-12-31 | $4 |
| 2021-09-30 | $3 |
| 2021-06-30 | $4 |
| 2021-03-31 | $3 |
| 2020-12-31 | $2 |
| 2020-09-30 | $2 |
| 2020-06-30 | $1 |
| 2020-03-31 | $2 |
| 2019-12-31 | |
| 2019-09-30 | $1 |
| 2018-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.237B | $0.069B |
| Pulmonx Corporation is a medical technology company. It designs, develops, manufactures and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation is based in Redwood City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $8.497B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $5.276B | 164.53 |
| Hims & Hers Health (HIMS) | United States | $5.141B | 130.72 |
| Privia Health (PRVA) | United States | $2.533B | 211.10 |
| Enovis (ENOV) | United States | $2.529B | 17.15 |
| IRhythm Technologies (IRTC) | United States | $2.362B | 0.00 |
| Azenta (AZTA) | United States | $2.001B | 99.78 |
| Omnicell (OMCL) | United States | $1.964B | 64.26 |
| Clover Health Investments (CLOV) | United States | $1.644B | 0.00 |
| 10x Genomics (TXG) | United States | $1.643B | 0.00 |
| Schrodinger (SDGR) | United States | $1.378B | 0.00 |
| Phreesia (PHR) | United States | $1.072B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.650B | 0.00 |
| Standard BioTools (LAB) | United States | $0.562B | 0.00 |
| Talkspace (TALK) | United States | $0.522B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.520B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.483B | 83.60 |
| Health Catalyst (HCAT) | United States | $0.459B | 0.00 |
| TruBridge (TBRG) | United States | $0.244B | 71.22 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.214B | 0.00 |
| American Well (AMWL) | United States | $0.122B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.107B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.075B | 0.00 |
| HeartBeam (BEAT) | United States | $0.067B | 0.00 |
| 111 (YI) | China | $0.053B | 0.00 |
| CareCloud (CCLD) | United States | $0.046B | 0.00 |
| Zepp Health (ZEPP) | China | $0.040B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.040B | 0.00 |
| Outset Medical (OM) | United States | $0.039B | 0.00 |
| Movano (MOVE) | United States | $0.020B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.019B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.014B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.012B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.006B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.004B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |